Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
News
-
March 15, 2023Targovax ASA: circRNA poster to be presented at the AACR Annual Meeting
-
March 14, 2023Targovax: First patient dosed with TG01 in the USA
-
March 9, 2023Targovax ASA – First Tranche of Convertible Bonds
-
March 9, 2023Targovax ASA: Minutes from the Extraordinary General Meeting
Q4 Fourth Quarter 2022
Targovax announced its fourth quarter 2022 results on Thursday 16 February 2023.
Webcast: 10:00 a.m. CET the same day